Stat

Unpacking Tomorrow's Cancer Fight: Key Insights from AACR 2026

A Paradigm Shift: CAR T-Cell Therapy Offers New Hope for Stiff Person Syndrome

A New Dawn for Pancreatic Cancer: Unpacking the Revolutionary Science from AACR 2026

A Renewed Sense of Hope: Roche's Ocrevus Continues to Impress in MS Care

The Ripple Effect: How a Purdue Pharma Ruling Could Unsettle Pharma Settlements

A Digital Pioneer Departs: Andrew Baum's Exit from Pfizer

The Psychedelic Crossroads: Hope, Science, and the Shadow of Politics

Lilly's Strategic Gambit: Unpacking the Kelonia Therapeutics Partnership

The Quest for Hair: Nektar's Rezpeg Promises a New Dawn for Alopecia Sufferers

A New Era of Hope: Revolutionizing Pancreatic Cancer Treatment

A Game Changer? Allogene's 'Off-the-Shelf' CAR T Therapy Shows Stunning Promise in B-Cell Lymphoma

The Unraveling of Kezar Life Sciences: How an FDA Delay Triggered a Biotech Startup's Collapse

The Unspoken Irony: RFK Jr.'s Medical Freedom Paradox

Beyond the Dose: How Psychedelic Integration Coaches Are Revolutionizing Ketamine Therapy for Depression

Takeda Announces Significant Job Cuts, Centered on Cambridge R&D

Eli Lilly's Cancer Revolution: How Loxo Oncology Reshaped an Empire

The Unforeseen Ripple: How Trump's Drug Pricing Push Could Have Raised Global Costs

When Geopolitics Hits Home: The Unsettling Shadow of an Iran Conflict on Our Medicine Cabinet

Hims & Hers Steps into the Doctor's Office: Convenience vs. Comprehensive Care

A Glimmer of Hope for Kidney Disease: Vertex's Breakthrough in IgA Nephropathy

The FDA's Quiet Retreat: Fewer Public Debates Amid Rising Controversy

The Price of Life: Will South Africa Gain Access to Gilead's Breakthrough HIV Drug?

Virginia's Bold Move: A New Era for Prescription Drug Affordability

The Shifting Sands of Pharma: FDA's Grip, Global Ambitions, and the Future of Medicine

A Major Setback: FDA Halts uniQure's Huntington's Gene Therapy Trial

The End of an Era: Doug Ingram Prepares to Retire from Sarepta, Elizabeth Barrett Named Successor

GSK's Bold Move: A $1.8 Billion Bet on the Future of Pulmonary Hypertension Treatment

A Looming Showdown: Can RFK Jr. and Dr. Maha Force the FDA to Confront the Ultra-Processed Food Crisis?

The Shifting Tides of American Health: What's Next for HHS Post-2026?

A Game-Changer on the Horizon: Disc Medicine's Bitopertin and the FDA's Looming Decision

Unpacking Trump's Vision for 340B: A Pilot Program's Complex Ripples

Pharmalot's Pulse Check: Navigating Pharma's Twists and Turns

The Shifting Sands of Pharma: Innovation, Access, and Lingering Questions in Early 2026

The Pharmaceutical Frontier: Navigating Breakthroughs, Billions, and Bitter Debates

The J.P. Morgan Healthcare Conference 2026: Day 2 Unpacked

Unlocking New Frontiers: How Revolution Medicines and Merck Are Redefining the Cancer Fight

Alnylam's Ambitious Five-Year Vision: Betting Big on Amvuttra and Beyond

The Evolving Landscape of Pharma and Biotech Employment

Unpacking the Ambition: Trump's Most-Favored-Nation Drug Pricing Push